Increased circulating endothelial progenitor cells in patients with bacterial pneumonia: evidence that bone marrow derived cells contribute to lung repair

M Yamada, H Kubo, K Ishizawa, S Kobayashi, M Shinkawa, H Sasaki


Inflammatory stimuli rapidly induce a massive release of inflammatory cells from the bone marrow. These inflammatory cells are important for host defence and resolution of an inflammatory response. It has recently become recognised that the bone marrow is a source of progenitor cells for several cell types including endothelial and epithelial cells. We have previously shown that administration of lipopolysaccharide (LPS) to murine lungs induced a rapid release of endothelial progenitor cells (EPCs) into the circulation and that bone marrow derived progenitor cells including EPCs contribute to lung repair after lung injury in mice. This study was undertaken to investigate the mobilisation of EPCs in humans following acute pneumonia.

Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from venous blood taken from 23 patients with pneumonia during both the acute and convalescent phases. One million PBMCs were plated on fibronectin coated culture slides and cultured in culture medium for endothelium. The numbers of EPCs were counted 8 days after plating.

Results: The number of circulating EPCs significantly increased in patients with pneumonia (p<0.0001). Patients with low EPC counts tended to have persistent fibrotic changes in their lungs even after their recovery from pneumonia.

Conclusions: Inflammatory stimuli induce a rapid release of EPCs into the circulation in humans. A sufficient number of EPCs is necessary for proper lung repair following bacterial pneumonia.

Background: Tissue repair often occurs in organs damaged by various inflammatory diseases including pneumonia. Inflammatory stimuli induce a rapid and massive release of inflammatory cells from the bone marrow. Recent studies have suggested that bone marrow cells have the potential to differentiate into a variety of cell types. It has been shown that administration of lipopolysaccharide (LPS) to murine lungs induces a rapid release of endothelial progenitor cells (EPCs) into the circulation, and that bone marrow derived progenitor cells including EPCs contribute to lung repair after lung injury in mice. This study was undertaken to investigate the mobilisation of EPCs in humans following acute pneumonia.

Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from venous blood taken from 23 patients with pneumonia during both the acute and convalescent phases. One million PBMCs were plated on fibronectin coated culture slides and cultured in culture medium for endothelium. The numbers of EPCs were counted 8 days after plating.

Results: The number of circulating EPCs significantly increased in patients with pneumonia (p<0.0001). Patients with low EPC counts tended to have persistent fibrotic changes in their lungs even after their recovery from pneumonia.

Conclusions: Inflammatory stimuli induce a rapid release of EPCs into the circulation in humans. A sufficient number of EPCs is necessary for proper lung repair following bacterial pneumonia.

Cell culture assay for circulating EPCs

Isolation of EPCs was performed mainly according to the method previously reported. Briefly, a 10 ml sample of venous blood was collected from the patients to isolate EPCs. Blood was collected before treatment and 8 weeks after treatment was completed. At the time of the first sampling the duration of the illness was less than 28 hours (median 24 hours; range 17–28 hours). Samples were processed within 6 hours of collection and peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Ficoll (Amersham Biosciences, Piscataway, NJ, USA). Isolated cells were suspended in endothelial growth medium and 106 cells/well were plated on 4-well culture slides coated with fibronectin (Biocoat, BD Labware, Franklin Lakes, NJ, USA). The number of EPCs per mm2 on the culture slide was counted 8 days after plating and, after determining the number of PBMCs in 10 ml peripheral blood and the number of EPCs in 106 mononuclear cells, we also calculated the number of EPCs obtained from 1 ml of blood. Confirmation of endothelial cell lineage was performed using the HRCT scan images. We defined the linear and reticular opacity based on HRCT scan images as fibrotic change. Subjects were excluded if their clinical course was suggestive of atypical pneumonia. We also excluded subjects with cardiovascular disease, cancer, or diabetes because these diseases have been reported to influence circulating EPC counts. All subjects signed an informed consent document approved by the local ethics committee of the Tohoku University School of Medicine.

Abbreviations: CRP, C-reactive protein; EPC, endothelial progenitor cell; LPS, lipopolysaccharide; PBMC, peripheral blood mononuclear cell; PSI, pneumonia severity index.
performed by double positive staining for 1,1-dioctadecyl-
3,3',3'-tetramethylindocarbocyanin labelled acetylated low
density lipoprotein (Dil-acDL; 2.4 μg/ml; Sigma, St Louis,
MO, USA) and FITC-labelled lectin (10 μg/ml; Sigma). We
also performed immunostaining against vascular endothelial
growth factor receptors 2 and CD31 which are considered to
be markers of endothelial cell lineage.

Analysis of data
Values are expressed as median (25–75th interquartile range,
IQR) unless otherwise indicated. Individual comparisons
were performed using the non-parametric Wilcoxon signed
rank test. Correlations between the number of EPCs before
treatment and white blood cell counts, C-reactive protein
(CRP), age, PSI, CURB-65 score, blood monocyte counts, and
blood lymphocyte counts were analysed with the Spearman
rank correlation test. The non-parametric Wilcoxon rank sum
test was used for comparisons of continuous variables and
Fisher’s exact test for comparisons of categorical variables
between the groups with low and high EPC counts.

RESULTS AND DISCUSSION
Characteristics of patients
Twenty three adult patients with moderately severe commu-
nity acquired bacterial pneumonia were enrolled in the study
(table 1). The mean age of the patients was 73.0 years
(median 76, range 30–95, IQR 65–80). None of the patients
had coexisting illnesses such as neoplastic disease, cardio-
vacular disease, diabetes, liver disease, cerebrovascular
disease, or renal disease. None were receiving concurrent
medication or had received prior antibiotic treatment, and
none were smokers. All patients were febrile at the time of
the first sampling (median 38.3°C, range 37.6–38.9). The
mean initial PSI was 78.6 (median (76 (IQR 65–92)). Four patients had a
CURB-65 score of 0, six had a score of 1, and 13 had a score of 2. Bacterial examinations of the sputum revealed Streptococcus
pneumoniae in six patients, Haemophilus influenzae in two and
Moraxella catarrhalis in one patient. In 14 patients we could
not identify a causal organism.

Circulating EPCs at acute phase in patients with
pneumonia
Flat and spindle-like attaching cells appeared in cultured
PBMCs. The morphological appearance of attaching cells
resembled that of EPCs previously reported. 31 0 We further
reported in mice. 3

We then determined whether the number of EPCs
correlated with other factors including pre-treatment labora-
tory data. The number of EPCs was not significantly
correlated with peripheral blood white blood cell (WBC)
counts or CRP, which are considered indicators of the extent
of inflammation (WBC counts: p = 0.387, p = 0.1692; CRP:
p = 0.009, p = 0.9649). The severity of pneumonia (PSI,
CURB-65) was also not significantly correlated with the
number of EPCs (PSI: p = −0.247, p = 0.4641; CURB-65:
p = 0.190, p = 0.3722). We also observed a weak inverse
correlation between the subjects’ age and the number of
EPCs, but this relationship was not statistically significant
(p = −0.255, p = 0.1016). Interestingly, there was a strong
correlation between peripheral blood monocyte counts and
the number of EPCs (p = 0.635, p = 0.0029; fig 1K). We also
observed a correlation between peripheral blood lymphocyte
counts and the number of EPCs (p = 0.784, p = 0.0002;
fig 1L). The finding that pre-treatment EPC counts in our
patients were strongly correlated with monocyte and
lymphocyte counts suggests that mechanisms of EPC
mobilisation from bone marrow may resemble mechanisms
of monocyte and lymphocyte mobilisation—mechanisms that
involve mediators such as stromal cell derived factor 1/CXCR4
axis.11

Lung fibrotic changes in patients with low EPC counts
We divided the subjects into two groups based on their pre-
treatment EPC counts to analyse the relationship between
EPC counts and the clinical characteristics of the patients
(table 1). The EPC count was not associated with sex, age,
peripheral blood WBC counts, serum CRP, serum albumin,

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All subjects†</th>
<th>Low EPC group†</th>
<th>High EPC group†</th>
<th>p value‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M:F)</td>
<td>12:11</td>
<td>6:6</td>
<td>6:6</td>
<td>0.99</td>
</tr>
<tr>
<td>Age (years)</td>
<td>76 (65–80)</td>
<td>77 (68–82)</td>
<td>73 (62–79)</td>
<td>0.21</td>
</tr>
<tr>
<td>WBC (10³/mm³)</td>
<td>11.7 (8–14.0)</td>
<td>11.7 (7.9–12.2)</td>
<td>13.0 (10.5–15.0)</td>
<td>0.13</td>
</tr>
<tr>
<td>Hb (g/dl)</td>
<td>11.1 (10–12.1)</td>
<td>11.2 (10.9–11.9)</td>
<td>11.6 (10.8–12.3)</td>
<td>0.51</td>
</tr>
<tr>
<td>Albumin (g/dl)</td>
<td>3.4 (3.1–4.0)</td>
<td>3.2 (2.7–3.7)</td>
<td>3.6 (3.2–4.0)</td>
<td>0.10</td>
</tr>
<tr>
<td>CRP (mg/dl)</td>
<td>11.1 (6.4–20.6)</td>
<td>11.4 (6.4–19.4)</td>
<td>12.6 (7.2–21.6)</td>
<td>0.69</td>
</tr>
<tr>
<td>SPCT (%)</td>
<td>93 (89–93)</td>
<td>93 (90–93)</td>
<td>93 (90–94)</td>
<td>0.60</td>
</tr>
<tr>
<td>PSI</td>
<td>76 (65–92)</td>
<td>77 (69–97)</td>
<td>71 (63–92)</td>
<td>0.51</td>
</tr>
<tr>
<td>CURB-65 score</td>
<td>5 (0 or 1)</td>
<td>5</td>
<td>5</td>
<td>0.99</td>
</tr>
<tr>
<td>Patients with persistent fibrotic changes</td>
<td>7</td>
<td>6</td>
<td>1</td>
<td>0.027</td>
</tr>
</tbody>
</table>

Table 1 Characteristics of patients according to EPC counts (n = 23)*

*CRP, C-reactive protein; Hb, haemoglobin; PSI, pneumonia severity index.
†Values are expressed as median (25–75th IQR) unless otherwise indicated.
‡Pretreatment EPC counts: 2298 (1602–3820)/ml blood in all subjects, 1523 (1039–2206)/ml blood in the low EPC group, and 3687 (2656–4788)/ml blood in the high EPC group.
§Non-parametric Wilcoxon rank sum test was used for comparisons of continuous variables and Fisher’s exact test was used for comparisons of categorical variables.
percutaneous oxygen saturation, or the severity of pneumonia (PSI, CURB-65). Similarly, EPC counts were not significantly associated with the infecting organism (data not shown).

We also analysed the relation between EPC counts and the patients' state after recovery from pneumonia. Interestingly, patients with low pre-treatment EPC counts tended to have persistent fibrotic changes in their lung, based on HRCT scan images, even after they had recovered. We have previously shown that suppression of bone marrow derived progenitor cells, including EPCs, caused incomplete repair from LPS induced lung injury. 

Several reports have suggested that EPC counts could provide a marker of vascular function in ischaemic stress. Although the nature and size of the present study does not permit us to determine whether EPC levels can accurately predict the adequacy of repair of lung injury caused by pneumonia, the data suggest that bone marrow derived progenitor cells, including EPCs, contribute to lung repair following bacterial pneumonia, and that the levels of EPCs may predict the ability for lung repair following injury.

In this study we have shown that there is a strong correlation between peripheral blood lymphocyte counts and the number of EPCs. It is widely known that lymphocytopenia is a poor prognostic factor in infectious diseases including bacterial pneumonia. Because our data showed that suppression of EPCs might cause incomplete repair from pneumonia, we speculate that a poor prognosis in pneumonia patients with lymphocytopenia may be due to a reduction in the ability of the lung to repair that is thought to be correlated with EPC counts.

Authors' affiliations
M Yamada, H Kubo, K Ishizawa, S Kobayashi, M Shinkawa, H Sasaki, Department of Geriatric and Respiratory Medicine, Tohoku University School of Medicine, Sendai, 980-8574, Japan

This work was supported by a grant from the Japan Society for the Promotion of Science No 13670589 to HK.

The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or the writing of the report.

REFERENCES


Figure 1  Circulating endothelial progenitor cells (EPCs) were increased at the acute phase in patients with pneumonia. Representative images of EPCs in pre-treatment (A–D) and post-treatment (E–H) samples from a patient with pneumonia. Differential interference contrast (DIC) images (A, E), acLDL uptake (B, F; red), lectin binding (C, G; green), and acLDL uptake/lectin binding overlay images (D, H; yellow) of EPCs are shown. The number of EPCs at the pre-treatment phase was significantly higher than at the post-treatment phase. Scale bars 25 μm. (I, J) Pre-treatment and post-treatment EPCs were isolated from the peripheral blood of 23 patients with bacterial pneumonia. (I) Number of EPCs per mm² and (J) number of EPCs per ml blood after adjustment for the number of mononuclear cells in peripheral blood. p values were calculated with the non-parametric Wilcoxon signed rank test. Correlation between the number of EPCs and (K) peripheral blood monocytes or (L) lymphocytes in patients with pneumonia showing Spearman’s rho (ρ) and p values.  

www.thoraxjnlll.com
Role of endothelial progenitor cells in lung repair


LUNG ALERT

Asthma deaths and bronchodilator therapy


This study concerning asthma deaths and bronchodilator therapy covered 33 health boards in the UK (27% of population) for 4 years from 1994 to 1998. Patients had asthma as the principal cause of death (at certification), were under the age of 65, with no other underlying non-respiratory cause. Data were gathered for the 5 year period before death using hospital and primary care sources. This group was then matched with controls from the local hospital discharged with a diagnosis of asthma within the same time period and of the same age. When matching for severity, the age of onset of asthma, presence of chronic obstructive disease, previous hospital admissions for asthma, and the number of medications prescribed were used. The total number of deaths included was 532 (22% were excluded), of which 44% occurred in hospital. It was noted that those who died had an earlier age of onset of asthma, mention of obesity, and evidence of associated chronic obstructive pulmonary disease.

Short acting β₂ agonist treatment prescribed 1–5 years before death was associated with an increased risk of mortality (odds ratio 2.05, 95% CI 1.26 to 3.33, p<0.01). No such association was noted during the year preceding death. Inhaled corticosteroids showed no evidence of an altered risk of mortality, but there was a suggestion that long acting β₂ drugs may be associated with a decrease in mortality risk. A number of possible explanations may underlie the observed association between short acting β₂ agonist therapy and mortality, only one of which is a direct toxic effect of the drugs themselves.

G Price
Locum Registrar, Royal London Hospital, London, UK; graniaprice@doctors.org.uk